1 | Tralokinumab | 1件: Tralokinumab Tralokinumab | 1件: Tralokinumab
Tralokinumab
💬
| 1件: IL13 IL13 💬
| 8件: Asthma Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬 | 2件: 85 85, 97 💬
|
2 | Tralokinumab cohort 1 | 1件: Tralokinumab Tralokinumab | 1件: Tralokinumab
Tralokinumab
💬
| 1件: IL13 IL13 💬
| 8件: Asthma Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬 | 1件: 85 85 💬
|
3 | Tralokinumab cohort 2 | 1件: Tralokinumab Tralokinumab | 1件: Tralokinumab
Tralokinumab
💬
| 1件: IL13 IL13 💬
| 8件: Asthma Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬 | 1件: 85 85 💬
|
4 | Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor | 1件: Tralokinumab Tralokinumab | 1件: Tralokinumab
Tralokinumab
💬
| 1件: IL13 IL13 💬
| 8件: Asthma Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬 | 1件: 85 85 💬
|